Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The document serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline Performance Share Plan (PSP).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed is the share price used for tax-related sales: £14.75 per Ordinary Share.
Material Changes
The filing details the sale of Ordinary Shares by specific executives to meet tax liabilities following the vesting of 2010 PSP awards on March 5, 2013. The transactions involved the following individuals:
- Mr R Connor: 372 shares sold
- Mr P Thomson: 319 shares sold
- Dr P Vallance: 10,983 shares sold
- Ms E Walmsley: 14,095 shares sold
- Mrs V Whyte: 319 shares sold
Additionally, PSP administrators notified the company that Dr Vallance and Ms Walmsley each received one additional vested share beyond the amount initially announced on March 5, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Confirm the total number of shares sold by PDMRs to meet tax obligations.
- Verify the share price of £14.75 used for the March 5, 2013 transactions.
- Note the correction regarding the additional vested shares awarded to Dr Vallance and Ms Walmsley.